Histocell

Histocell is a private, revenue-generating company positioned at the intersection of advanced therapy development and contract manufacturing. It has built a dual business model encompassing proprietary regenerative medicine programs (cell therapies, secretome-based products, medical devices) and a full-service CDMO platform with recent GMP certification for iPSC master and working cell bank production. Key strategic moves include the 2023 authorization of a new 800 m² GMP manufacturing plant and a significant partnership with Japan's REPROCELL, strengthening its role as a European hub for cell therapy manufacturing. The company targets wound healing, dermatology, and broader regenerative indications through its integrated platform.

Proprietary cell therapy and secretome platforms; GMP CDMO platform with certified manufacturing for cell therapies, biological products, and clinical-grade iPSC Master/Working Cell Banks (via REPROCELL's StemRNA™ technology).

Histocell competes with large multinational CDMOs (e.g., Lonza, Catalent) and specialized cell therapy CMOs in Europe and the US. Its differentiation lies in its integrated model (proprietary R&D + CDMO), specific focus on iPSC banking via its exclusive REPROCELL partnership, and its modern, EU-certified facility dedicated to advanced therapies.